RJA
STML

Raymond James & Associates’s Stemline Therapeutics, Inc. STML Stock Holding History

Raymond James & Associates’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-16,150
Closed -$247K – 3768
2019
Q2 		$247K Buy
+16,150
New +$234K ﹤0.01% 3122

Other funds holding STML

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Raymond James & Associates's STML Position: Q3 2019 in Review

Raymond James & Associates sold out of Stemline Therapeutics, Inc. (STML) in Q3 2019, closing a stake of 16,150 shares — an estimated $247K sold.

Raymond James & Associates first reported a position in STML in Q2 2019 and held it in 1 quarter. The position peaked at $247K in Q2 2019. 100 funds tracked by Wall St. Rank hold STML as of Q3 2019.

  • Raymond James & Associates reported no remaining Stemline Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
  • Raymond James & Associates sold 16,150 Stemline Therapeutics, Inc. shares in Q3 2019, an estimated $247K.
  • Raymond James & Associates first reported a position in Stemline Therapeutics, Inc. in Q2 2019 and held it in 1 quarter.
  • Raymond James & Associates's Stemline Therapeutics, Inc. position peaked at $247K in Q2 2019.
  • 100 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q3 2019.

Based on Raymond James & Associates's 13F filing for Q3 2019, filed 7 Nov 2019.